Authors

• Sheng Gao (ORCID: https://orcid.org/0000-0002-8622-5694)
• F. Lavie (ORCID: https://orcid.org/0000-0002-5213-257X)
• Warner Chen
• Stefan Siebert (ORCID: https://orcid.org/0000-0002-1802-7311)
• Proton Rahman (ORCID: https://orcid.org/0000-0002-4521-2029)
• Mónica Gumá (ORCID: https://orcid.org/0000-0003-1951-9411)
• Soumya D. Chakravarty (ORCID: https://orcid.org/0000-0001-7957-838X)
• S. P. Raychaudhuri
• G. Schett

Institutions

• Memorial University of Newfoundland (CA)
• Johnson & Johnson (United States) (US)
• Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
• University of California San Diego (US)
• Universitätsklinikum Erlangen (DE)
• Janssen (France) (FR)
• Springhouse (US)
• Janssen (United States) (US)
• VA Northern California Health Care System (US)
• Janssen Scientific Affairs (United States)
• Drexel University (US)
• University of Glasgow (GB)
• University of California, Davis (US)

Publication Details

Journal

Therapeutic Advances in Musculoskeletal Disease

Published

2024-10-01

DOI

https://doi.org/10.1177/1759720x241283536

Citations

3

Primary Topic

Dermatology and Skin Diseases

Type

article

Field-Weighted Citation Impact

1.60

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Gilead Sciences
• Celgene
• Janssen Scientific Affairs
• Teijin Pharma
• Genentech
• Janssen Research and Development